Style | Citing Format |
---|---|
MLA | Shaernejad S, et al.. "Role of Hesperidin/Hesperetin Against Chemotherapy-Induced Cardiotoxicity: A Systematic Review of Non-Clinical Studies." Cancer Cell International, vol. 25, no. 1, 2025, pp. -. |
APA | Shaernejad S, Nosrat A, Baeeri M, Hashemi Goradel N, Seyedsadeghi M, Akbariani M, Arabzadeh A, Rahimifard M, Haghiaminjan H (2025). Role of Hesperidin/Hesperetin Against Chemotherapy-Induced Cardiotoxicity: A Systematic Review of Non-Clinical Studies. Cancer Cell International, 25(1), -. |
Chicago | Shaernejad S, Nosrat A, Baeeri M, Hashemi Goradel N, Seyedsadeghi M, Akbariani M, Arabzadeh A, Rahimifard M, Haghiaminjan H. "Role of Hesperidin/Hesperetin Against Chemotherapy-Induced Cardiotoxicity: A Systematic Review of Non-Clinical Studies." Cancer Cell International 25, no. 1 (2025): -. |
Harvard | Shaernejad S et al. (2025) 'Role of Hesperidin/Hesperetin Against Chemotherapy-Induced Cardiotoxicity: A Systematic Review of Non-Clinical Studies', Cancer Cell International, 25(1), pp. -. |
Vancouver | Shaernejad S, Nosrat A, Baeeri M, Hashemi Goradel N, Seyedsadeghi M, Akbariani M, et al.. Role of Hesperidin/Hesperetin Against Chemotherapy-Induced Cardiotoxicity: A Systematic Review of Non-Clinical Studies. Cancer Cell International. 2025;25(1):-. |
BibTex | @article{ author = {Shaernejad S and Nosrat A and Baeeri M and Hashemi Goradel N and Seyedsadeghi M and Akbariani M and Arabzadeh A and Rahimifard M and Haghiaminjan H}, title = {Role of Hesperidin/Hesperetin Against Chemotherapy-Induced Cardiotoxicity: A Systematic Review of Non-Clinical Studies}, journal = {Cancer Cell International}, volume = {25}, number = {1}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Shaernejad S AU - Nosrat A AU - Baeeri M AU - Hashemi Goradel N AU - Seyedsadeghi M AU - Akbariani M AU - Arabzadeh A AU - Rahimifard M AU - Haghiaminjan H TI - Role of Hesperidin/Hesperetin Against Chemotherapy-Induced Cardiotoxicity: A Systematic Review of Non-Clinical Studies JO - Cancer Cell International VL - 25 IS - 1 SP - EP - PY - 2025 ER - |